BerGenBio ASA (OTCMKTS:BRRGF) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 346,900 shares, an increase of 29.4% from the March 31st total of 268,100 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.
Separately, HC Wainwright restated a “buy” rating on shares of BerGenBio ASA in a research report on Monday, March 8th.
OTCMKTS:BRRGF opened at $3.52 on Wednesday. The stock has a fifty day moving average price of $3.52 and a 200 day moving average price of $3.54. BerGenBio ASA has a 12-month low of $2.95 and a 12-month high of $4.39.
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19.
Recommended Story: Index Funds
Receive News & Ratings for BerGenBio ASA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BerGenBio ASA and related companies with MarketBeat.com's FREE daily email newsletter.